GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Kaibao Pharmaceutical Co Ltd (SZSE:300039) » Definitions » Cash And Cash Equivalents

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Cash And Cash Equivalents : ¥800 Mil (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Shanghai Kaibao Pharmaceutical Co Cash And Cash Equivalents?

Shanghai Kaibao Pharmaceutical Co's quarterly cash and cash equivalents increased from Sep. 2023 (¥571.46 Mil) to Dec. 2023 (¥601.94 Mil) and increased from Dec. 2023 (¥601.94 Mil) to Mar. 2024 (¥799.69 Mil).

Shanghai Kaibao Pharmaceutical Co's annual cash and cash equivalents declined from Dec. 2021 (¥1,344.95 Mil) to Dec. 2022 (¥694.69 Mil) and declined from Dec. 2022 (¥694.69 Mil) to Dec. 2023 (¥601.94 Mil).


Shanghai Kaibao Pharmaceutical Co Cash And Cash Equivalents Historical Data

The historical data trend for Shanghai Kaibao Pharmaceutical Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Kaibao Pharmaceutical Co Cash And Cash Equivalents Chart

Shanghai Kaibao Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 809.52 1,307.08 1,344.95 694.69 601.94

Shanghai Kaibao Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 715.12 582.75 571.46 601.94 799.69

Shanghai Kaibao Pharmaceutical Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Shanghai Kaibao Pharmaceutical Co  (SZSE:300039) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Shanghai Kaibao Pharmaceutical Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Shanghai Kaibao Pharmaceutical Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Business Description

Traded in Other Exchanges
N/A
Address
88 Chengpu Road, Shanghai Industrial Comprehensive Development Zone, Shanghai, CHN, 201401
Shanghai Kaibao Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in research, development, production, and sales of modern Chinese medicine. The company produces traditional Chinese medicines in the form of solid dosage, oral liquids, and small volume injections. Its main product is Tanreqing injection is mainly used for pneumonia, acute and chronic bronchitis and upper respiratory tract infection.
Executives
Liu Shao Yong Supervisors
Ren Li Wang Secretary Dong
Zhang Tao Executives
Mu Jing Wei Director
Li Xiu Hai Directors, executives
Zhang Lian Xin Supervisors
Han Jing Independent director
Wang Guo Ming Directors, executives
Wang Chong Bang Executives
Liu Yi Shan Director
Li Qing Wei Independent director
Mu Lai An Director
Zhu Ying Jun Executives
Chang Qing Ling Supervisors
Zhang Peng Director

Shanghai Kaibao Pharmaceutical Co (SZSE:300039) Headlines

No Headlines